Drug interactions
Momelotinib + Rimegepant
Severity: Moderate
Momelotinib and Rimegepant: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Momelotinib inhibits BCRP and may increase exposure to BCRP substrates. Rimegepant is a BCRP substrate, so levels could rise modestly, but protein-binding displacement is not a relevant mechanism.
What this interaction means in plain words
Momelotinib and Rimegepant can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Momelotinib belongs to Oncology; Rimegepant belongs to Central Nervous System.
Why it happens
Inhibition of BCRP efflux transport, which may increase rimegepant absorption.
What to do
Avoid repeat rimegepant dosing within 48 hours and monitor for adverse effects.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Momelotinib and Rimegepant, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Rimegepant
Other interactions of Momelotinib
- Atorvastatin + Momelotinib Moderate
- Clarithromycin + Momelotinib Moderate
- Cyclosporin + Momelotinib Moderate
- Daunorubicin + Momelotinib Moderate
- Erythromycin + Momelotinib Moderate
- Fluvastatin + Momelotinib Moderate
Frequently asked questions
Can I take Momelotinib with Rimegepant?
MediHelp rates the interaction as moderate. Momelotinib and Rimegepant can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Momelotinib inhibits BCRP and may increase exposure to BCRP substrates. Rimegepant is a BCRP substrate, so levels could rise modestly, but protein-binding displacement is not a relevant mechanism.
How serious is the interaction between Momelotinib and Rimegepant?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid repeat rimegepant dosing within 48 hours and monitor for adverse effects.
What other medicines interact with Rimegepant?
MediHelp also lists interactions of Rimegepant with, for example, Amobarbital, Atazanavir, Butabarbital. The full list is on the Rimegepant page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
